Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M. Hagege A, et al. Among authors: luciano f. Cell Rep Med. 2022 Sep 20;3(9):100659. doi: 10.1016/j.xcrm.2022.100659. Cell Rep Med. 2022. PMID: 36130479 Free PMC article.
The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, He X, Bourget I, Rousset J, Saada E, Rastoin O, Parola J, Luciano F, Cao Y, Pagès G, Dufies M. Hagege A, et al. Among authors: luciano f. Theranostics. 2021 Sep 21;11(19):9571-9586. doi: 10.7150/thno.61711. eCollection 2021. Theranostics. 2021. PMID: 34646387 Free PMC article.
ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines.
Dufies M, Ambrosetti D, Boulakirba S, Calleja A, Savy C, Furstoss N, Zerhouni M, Parola J, Aira-Diaz L, Marchetti S, Orange F, Lacas-Gervais S, Luciano F, Jacquel A, Robert G, Pagès G, Auberger P. Dufies M, et al. Among authors: luciano f. Oncotarget. 2017 Dec 23;9(13):10920-10933. doi: 10.18632/oncotarget.23650. eCollection 2018 Feb 16. Oncotarget. 2017. PMID: 29541386 Free PMC article.
Mechanism of action of the multikinase inhibitor Foretinib.
Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P. Dufies M, et al. Among authors: luciano f. Cell Cycle. 2011 Dec 1;10(23):4138-48. doi: 10.4161/cc.10.23.18323. Epub 2011 Dec 1. Cell Cycle. 2011. PMID: 22101270
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P. Cluzeau T, et al. Among authors: luciano f. Oncotarget. 2012 Apr;3(4):490-501. doi: 10.18632/oncotarget.481. Oncotarget. 2012. PMID: 22577154 Free PMC article.
154 results